Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, together with its subsidiaries, focuses on acquiring, developing, and commercializing branded prescription products for hospital acute care, gastroenterology, and oncology markets in the United States and internationally. Its marketed products include Acetadote (acetylcysteine) injection for the treatment of acetaminophen poisoning; Caldolor (ibuprofen) injection for the treatment of pain and fever; Kristalose (lactulose) for the treatment of chronic and acute constipation; Vaprisol (conivaptan) injection for treating hyponatremia; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Ethyol (amifostine) for injection to treat oncology patients; and Totect Injection for the treatment of toxic effects. The company's product candidates in Phase II clinical trials comprise Hepatoren (ifetroban) injection for the treatment of hepatorenal syndrome; Boxaban (ifetroban) oral capsule for the treatment of aspirin-exacerbated respiratory disease; Vasculan (ifetroban) oral capsule for the treatment of systemic sclerosis; and Portaban for the treatment of portal hypertension. Its pre-approval products consist of RediTrexTM Methotrexate injection for treating active rheumatoid, juvenile idiopathic, and psoriatic arthritis, as well as disabling psoriasis. The company markets and sells its products through sales representatives and district managers. Cumberland Pharmaceuticals Inc. has a strategic alliance with Clinigen Group plc and Nordic Group B.V. The company was incorporated in 1999 and is headquartered in Nashville, Tennessee.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Current SymbolNASDAQ:CPIX
Previous Symbol
CUSIP23077010
Phone615-255-0068
Debt
Debt-to-Equity Ratio0.21
Current Ratio4.10
Quick Ratio3.69
Price-To-Earnings
Trailing P/E Ratio-86.86
Forward P/E Ratio-20.97
P/E GrowthN/A
Sales & Book Value
Annual Sales$41.15 million
Price / Sales2.29
Cash Flow$0.1031 per share
Price / Cash Flow58.98
Book Value$4.06 per share
Price / Book1.50
Profitability
EPS (Most Recent Fiscal Year)($0.07)
Net Income$-7,970,000.00
Net Margins-14.25%
Return on Equity-4.68%
Return on Assets-3.13%
Miscellaneous
Employees84
Outstanding Shares15,530,000
Market Cap$95.96 million
OptionableOptionable
Cumberland Pharmaceuticals (NASDAQ:CPIX) Frequently Asked Questions
What is Cumberland Pharmaceuticals' stock symbol?
Cumberland Pharmaceuticals trades on the NASDAQ under the ticker symbol "CPIX."
How were Cumberland Pharmaceuticals' earnings last quarter?
Cumberland Pharmaceuticals, Inc. (NASDAQ:CPIX) issued its quarterly earnings results on Tuesday, November, 13th. The specialty pharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.19) by $0.14. The specialty pharmaceutical company had revenue of $8.49 million for the quarter, compared to analyst estimates of $9.16 million. Cumberland Pharmaceuticals had a negative net margin of 14.25% and a negative return on equity of 4.68%. View Cumberland Pharmaceuticals' Earnings History.
When is Cumberland Pharmaceuticals' next earnings date?
What price target have analysts set for CPIX?
1 brokers have issued twelve-month price targets for Cumberland Pharmaceuticals' stock. Their predictions range from $8.75 to $8.75. On average, they anticipate Cumberland Pharmaceuticals' share price to reach $8.75 in the next twelve months. This suggests a possible upside of 43.9% from the stock's current price. View Analyst Price Targets for Cumberland Pharmaceuticals.
What is the consensus analysts' recommendation for Cumberland Pharmaceuticals?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cumberland Pharmaceuticals in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cumberland Pharmaceuticals.
Has Cumberland Pharmaceuticals been receiving favorable news coverage?
News articles about CPIX stock have been trending positive on Wednesday, according to InfoTrie. The research firm identifies negative and positive news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Cumberland Pharmaceuticals earned a media sentiment score of 2.6 on InfoTrie's scale. They also assigned media coverage about the specialty pharmaceutical company a news buzz of 3.0 out of 10, meaning that recent news coverage is unlikely to have an effect on the company's share price in the near term.
Who are some of Cumberland Pharmaceuticals' key competitors?
Some companies that are related to Cumberland Pharmaceuticals include ZEALAND PHARMA/S (ZEAL), MediciNova (MNOV), Evolus (EOLS), Clementia Pharmaceuticals (CMTA), American Brivision (Holding) (ABVC), resTORbio (TORC), Aclaris Therapeutics (ACRS), OptiNose (OPTN), Verastem (VSTM), Marker Therapeutics (MRKR), Keryx Biopharmaceuticals (KERX), Stemline Therapeutics (STML), Seres Therapeutics (MCRB), Aratana Therapeutics (PETX) and Minerva Neurosciences (NERV).
Who are Cumberland Pharmaceuticals' key executives?
Cumberland Pharmaceuticals' management team includes the folowing people:
- Mr. A. J. Kazimi, Founder, Chairman, CEO & Pres (Age 60)
- Mr. Michael P. Bonner, CFO & Sr. Director of Fin. & Accounting (Age 41)
- Mr. Leo B. Pavliv, Chief Devel. Officer & Exec. VP of Operations (Age 57)
- Mr. James Lowrance Herman, Chief Compliance Officer & Sr. VP of National Accounts (Age 63)
- Mr. Martin E. Cearnal, Exec. VP, Chief Commercial Officer & Director (Age 73)
Who are Cumberland Pharmaceuticals' major shareholders?
Cumberland Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional investors include Stonepine Capital Management LLC (7.85%), BlackRock Inc. (2.03%) and Acadian Asset Management LLC (0.63%). Company insiders that own Cumberland Pharmaceuticals stock include Kenneth Krogulski, Michael Bonner and Thomas R Lawrence. View Institutional Ownership Trends for Cumberland Pharmaceuticals.
Which major investors are selling Cumberland Pharmaceuticals stock?
Which major investors are buying Cumberland Pharmaceuticals stock?
CPIX stock was bought by a variety of institutional investors in the last quarter, including Stonepine Capital Management LLC. Company insiders that have bought Cumberland Pharmaceuticals stock in the last two years include Kenneth Krogulski and Michael Bonner. View Insider Buying and Selling for Cumberland Pharmaceuticals.
How do I buy shares of Cumberland Pharmaceuticals?
Shares of CPIX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Cumberland Pharmaceuticals' stock price today?
One share of CPIX stock can currently be purchased for approximately $6.08.
How big of a company is Cumberland Pharmaceuticals?
Cumberland Pharmaceuticals has a market capitalization of $95.96 million and generates $41.15 million in revenue each year. The specialty pharmaceutical company earns $-7,970,000.00 in net income (profit) each year or ($0.07) on an earnings per share basis. Cumberland Pharmaceuticals employs 84 workers across the globe.
What is Cumberland Pharmaceuticals' official website?
How can I contact Cumberland Pharmaceuticals?
Cumberland Pharmaceuticals' mailing address is 2525 WEST END AVENUE SUITE 950, NASHVILLE TN, 37203. The specialty pharmaceutical company can be reached via phone at 615-255-0068 or via email at [email protected]
MarketBeat Community Rating for Cumberland Pharmaceuticals (NASDAQ CPIX)
MarketBeat's community ratings are surveys of what our community members think about Cumberland Pharmaceuticals and other stocks. Vote "Outperform" if you believe CPIX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CPIX will underperform the S&P 500 over the long term. You may vote once every thirty days.
